At least 2 out of every 3 patients of diabetes, have Subclinical Cardiovascular disease (CVD)2
Subclinical CVD Increases the Risk of CV Event by nearly 2-fold2

navya
Navya, 44
pratham
Pratham, 48
Vidya, 46
Ajay, 54
Priya, 48
Shekhar, 42

For patients with CV disease and type 2 diabetes,*
Jardiance® allows you to do more to protect your patients
from the risk of CV death†,1,2,6

Early and sustained reduction in CV death2-4

CV: Cardiovascular. RRR: Relative risk reduction. HR: Hazard ratio. CI: Confidence interval. MI: Myocardial infarction.
CAD: Coronary artery disease. PAD: Peripheral artery disease.

Primary outcome was reduction in CV events defined as composite endpoint of CV death, non-fatal MI, or non-fatal stroke.
Jardiance® reduced the relative risk of CV events by 14% (HR=0.86; 95.02% CI: 0.74, 0.99; p=0.04). CV death was significantly reduced by
38% with no significant difference in non-fatal MI or non-fatal stroke.1,2

* Adult patients with insufficiently controlled type 2 diabetes and CAD, PAD, or a history of MI or stroke.1,2

† The 38% RRR in CV death was achieved in the overall EMPA-REG OUTCOME® population for the duration of the trial.1,3

‡ Pooled data from 10 mg and 25 mg doses of Jardiance®; both doses showed a comparable reduction in the risk of CV death.1,2

§ A post-hoc analysis of data from the EMPA-REG OUTCOME® Trial by baseline HbA1c subgroups. EMPA-REG OUTCOME®
was not powered to show differences between sub-groups.2,4

|| Hazard ratios are related to CV death: HbA1c HR=0.67 (95% CI: 0.45, 0.99); HbA1c ≥9% HR=0.76 (95% CI: 0.44, 1.31); p=0.41 for interaction.4

1. Jardiance® approved prescribing information, Boehringer lngelheim India, Version 28th Feb, 2020.

2. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med.
2015;373(22):2117-2128.

3. Fitchett D, Inzucchi SE, Lachin JM, et al. Cardiovascular mortality reduction with empagliflozin in patients with type 2 diabetes and cardiovascular
disease. J Am Coll Cardiol. 2018;71(3):364-367.

4. Inzucchi SE, Kosiborod M, Fitchett D, et al. Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic control.
Circulation. 2018;138:1904-1907.

5. Claggett B, Lachin JM, Hantel S, et al. Long-term benefit of empagliflozin on life expectancy in patients with type 2 diabetes mellitus and
established cardiovascular disease: Survival estimates from the EMPA-REG OUTCOME® Trial. Circulation. 2018;138:1599-1601.

6. Piepoli MF, Hoes AW, Agewall S, et al. European Guidelines on cardiovascular disease prevention in clinicalpractice: The Sixth Joint Task Force of the
European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2016;37(29):2315-2381.

Empagliflozin and liraglutide have class I recommendation
to reduce the risk of death in T2DM with CVD1

Recommondations for glucose-lowering treatment for patients with diabetes

T2DM: Type 2 diabetes mellitus. HF: Heart failure. ACS: Acute coronary syndromes. GLP1-RA: Glucagon-like peptide 1 receptor agonists.
CV: Cardiovascular. CVD: Cardiovascular disease. DM: Diabetes mellitus. DPP-4: Dipeptidyl peptidase-4.
SGLT2: Sodium glucose co-transporter 2.

Jardiance® is indicated for the following: 1. As an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus.2
To reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease.2

a Class of recommendation. b Level of evidence.

1. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed
incollaboration with the EASD. Eur Heart J. 2019;00:1-69.

2. Jardiance® approved prescribing information, Boehringer Ingelheim India, Version 28th Feb, 2020.